Prime-Boost Interval Matters: A Randomized Phase 1 Study to Identify the Minimum Interval Necessary to Observe the H5 DNA Influenza Vaccine Priming Effect

DNA vaccines: A safe and efficient platform technology for responding to emerging infectious diseases

(2014) Julie E. Ledgerwood et al.   Human vaccines & immunotherapeutics

Flu transmission work is urgent

(2012) Yoshihiro Kawaoka   NATURE

Will Flu Papers Lead to New Research Oversight?

(2012) M. Enserink et al.   SCIENCE

A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial

(2011) Julie E. Ledgerwood et al.   JOURNAL OF INFECTIOUS DISEASES

DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials

(2011) Julie E Ledgerwood et al.   LANCET INFECTIOUS DISEASES

Induction of Broadly Neutralizing H1N1 Influenza Antibodies by Vaccination

(2010) C.-J. Wei et al.   SCIENCE

Cross-Neutralization of 1918 and 2009 Influenza Viruses: Role of Glycans in Viral Evolution and Vaccine Design

(2010) C.-J. Wei et al.   Science Translational Medicine

Comparative Efficacy of Neutralizing Antibodies Elicited by Recombinant Hemagglutinin Proteins from Avian H5N1 Influenza Virus

(2008) C.-J. Wei et al.   JOURNAL OF VIROLOGY